Key result
Dipyridamole shows no benefit over control for outcomes or ischemic deficits after subarachnoid hemorrhage.
RCT (n=677)
Single-blind
Answers are grounded in this paper and cite their sources.
Recent evidence has suggested that the delayed cerebral ischemic deficits that often follow surgery for aneurysmal subarachnoid hemorrhage (SAH) may be due to a proliferative vasculopathy. This vascular pathology may result from an interaction between the platelets and the vessel wall. A single-blind controlled trial of dipyridamole administration in 677 patients presenting with SAH (of whom 348 came to surgery) was undertaken to test the hypothesis that the modification of platelet behavior might reduce the incidence of ischemic deficits. Blind independent assessment of the outcome in the surgical group based on the Glasgow Outcome Scale and the specific neurological deficits revealed no significant differences between the control and treatment groups.
No takes yet. Share an insight, caveat, or question.
Shaw et al. (1985) conducted an RCT in Aneurysmal subarachnoid hemorrhage (n=677). Dipyridamole vs. Control was evaluated on Glasgow Outcome Scale and specific neurological deficits in the surgical group. Dipyridamole produced no significant differences compared to control in Glasgow Outcome Scale or postoperative ischemic deficits among 348 surgical patients with subarachnoid hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: